These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24243851)

  • 21. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.
    Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Taparia M; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Mirza I; Quest G; Nahirniak S; Ghosh S; Sandhu I
    Leuk Res; 2016 Jun; 45():47-52. PubMed ID: 27092851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
    Xu J; Jorgensen JL; Wang SA
    Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
    Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
    Freeman SD; Jovanovic JV; Grimwade D
    Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative surgical margins: Main course or just icing on the cake?
    Kooby DA; Maithel SK
    J Surg Oncol; 2016 Mar; 113(3):247. PubMed ID: 27094455
    [No Abstract]   [Full Text] [Related]  

  • 28. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
    Hokland P; Cotter F
    Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.
    Othus M; Wood BL; Stirewalt DL; Estey EH; Petersdorf SH; Appelbaum FR; Erba HP; Walter RB
    Leukemia; 2016 Oct; 30(10):2080-2083. PubMed ID: 27133827
    [No Abstract]   [Full Text] [Related]  

  • 30. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
    Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
    Tsirigotis P; Byrne M; Schmid C; Baron F; Ciceri F; Esteve J; Gorin NC; Giebel S; Mohty M; Savani BN; Nagler A
    Bone Marrow Transplant; 2016 Nov; 51(11):1431-1438. PubMed ID: 27295272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus on MRD in AML?
    Paietta E
    Blood; 2018 Mar; 131(12):1265-1266. PubMed ID: 29567752
    [No Abstract]   [Full Text] [Related]  

  • 34. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia.
    Steinbach D; Bader P; Willasch A; Bartholomae S; Debatin KM; Zimmermann M; Creutzig U; Reinhardt D; Gruhn B
    Clin Cancer Res; 2015 Mar; 21(6):1353-9. PubMed ID: 25501127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].
    Zhang R; Sun HQ; Li G; Bai FY; Yang Y; Jing Q; Shi YJ; Yang JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):959-63. PubMed ID: 21867623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is a nadir bone marrow required and, if so, what to do with residual disease?
    Luger SM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
    Nomdedéu JF; Hoyos M; Carricondo M; Bussaglia E; Estivill C; Esteve J; Tormo M; Duarte R; Salamero O; de Llano MP; García A; Bargay J; Heras I; Martí-Tutusaus JM; Llorente A; Ribera JM; Gallardo D; Aventin A; Brunet S; Sierra J;
    Leukemia; 2013 Nov; 27(11):2157-64. PubMed ID: 23584566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M; Katragadda L; Zou F; Xiong S; Chang M; Dai Y; Hsu JW; Moreb JS; Leather H; Murthy HS; Farhadfar N; Li Y; Hromas R; Brown RA; Cogle CR; Wingard JR
    Blood Cancer J; 2017 Nov; 7(12):634. PubMed ID: 29176662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.